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Supplementary Experimental Procedures 
Materials 
[3H]-dopamine was obtained from Perkin Elmer (Boston, MA) (7,8-[3H] at 30–50 
Ci/mmol). Hepes, half sodium salt, was a product of Roche Applied Science 
(Indianapolis, IN).  Ultra centrifugation grade sucrose was obtained from Fisher 
Chemicals (Fairlawn, NJ).  Sigma-Aldrich (St. Louis, MO) was the source for the 
following compounds: L-(+)-arabinose, ascorbic acid, atropine sulfate, bovine serum 
albumin (BSA), (-)-nicotine tartrate, nomifensine, mecamylamine, R(+)-SCH23390, 
streptomycin, ampicillin, chloramphenicol, kanamycin, tetracycline, yohimbine, prazosin, 
and pargyline.  Optiphase ‘SuperMix’ scintillation fluid was from Perkin Elmer Life 
Sciences. 
 
Bacterial Artificial Chromosome Recombineering and Transgenesis 
A bacterial artificial chromosome (BAC) RP24-149I12 containing the mouse α6 
nicotinic receptor subunit gene (Chrna6) was obtained from the BACPAC Resource 
Center (BPRC) at Children's Hospital Oakland Research Institute (Oakland, CA).  BAC 
recombineering was carried out using a Counter Selection BAC modification kit 
(Genebridges; Heidelberg, Germany).  Recombineering in bacteria utilizes endogenous 
recombination activity, and allows the insertion of exogenous DNA into the BAC without 
residual sequences such as selection markers (neo) or loxP sites.  α6 Leucine 280 (Leu9’) 
was mutated to a serine using a two-step selection/counter selection protocol.  First, a 15 
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bp stretch of α6 exon 5 (5’-gttctgctttctctc-3’) containing the coding sequence for V278 
through L282 was replaced with a cassette containing a tandem selection (neo)/counter 
selection (rpsL) marker.  The rpsL/neo cassette was amplified by PCR using oligos 
designed to engineer α6 exon 5 homology arms flanking the sequence between and 
including V278 to L282.  The oligo sequences were: forward primer: 5’-tt ttt tac ctt ccc 
tcc gac tgt ggc gag aaa gtg act ctt tgc atc tcc gcggccgc GGC CTG GTG ATG ATG GCG 
GGA TCG-3’, and reverse primer: 5’-ac gag aga tgt gga tgg gat ggt ctc tgt aat cac cag caa 
aaa gac agt gcggccgc TCA GAA GAA CTC GTC AAG AAG GCG-3’ (homology arms: 
lower case; NotI restriction site: underlined, lower case; rpsL/neo cassette priming 
sequence: upper case). 
Neo was used to select positive recombinants, and an engineered NotI restriction 
site pair flanking the selection cassette was used to confirm the location of the 
exogenously inserted DNA within the BAC.  In the second step, α6 exon 5 was restored 
using counter selection.  Bacterial cells were placed under selective pressure (via 
streptomycin sensitivity gained by insertion of the rpsL marker) to lose the neo-rpsL 
cassette and replace it with non-selectable DNA engineered to insert the Leu9’ to Ser 
(L280S) mutation.  Non-selectable DNA sense strand sequence was: 5’-tt ttt tac ctt ccc 
tcc gac tgt ggc gag aaa gtg act ctt tgc atc tcc gtt ctg TCA agc ttg act gtc ttt ttg ctg gtg att 
aca gag acc atc cca tcc aca tct ctc gt-3’ (L280S mutation in upper case, silent HindIII 
restriction site underlined).  The resultant strain harbored a BAC with no ectopic DNA in 
or around the α6 gene.  α6L9’S BAC DNA was confirmed to have the desired mutation by 
DNA sequencing, restriction mapping, and diagnostic PCR.  The α6 nicotinic receptor 
gene is directly adjacent to the β3 nicotinic receptor gene (Chrnb3).  To eliminate the 
possibility that any physiological or behavioral phenotypes of our transgenic mice could 
be attributed to the presence of extra copies of β3, but to retain the β3 locus, we silenced 
the β3 gene using homologous recombination.  β3 was silenced by replacing exon 1 
(containing the methionine initiation codon) with an ampicillin selection cassette.  An 
ampicillin marker derived from pCDNA3.1zeo was amplified by PCR using oligos 
designed to engineer β3 homology arms and diagnostic SbfI restriction sites flanking the 
ampicillin marker.  The oligo sequences were: forward primer: 5’-agc ctc aca aga cct gac 
agc tca ctg ggc atc agt gaa gtg cac cctgcagg GAC GTC AGG TGG CAC-3’ and reverse 
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primer: 5’-tga gag agt ggc act gag agc caa gaa gac ccg tag gaa gcc tgt cctgcagg GTC 
TGA CGC TCA GTG-3’ (homology arms: lower case; SbfI restriction site: underlined, 
lower case; ampicillin marker priming sequence: upper case).  Two additional genes 
(4921537P18Rik and Tex24) which are not expressed in brain are also contained on the 
final BAC construct.   
Injection-grade α6L9’S BAC DNA was prepared via double CsCl banding 
(Lofstrand Labs; Gaithersberg, MD).  To produce transgenic animals, BAC DNA was 
injected into the male pronucleus of recently fertilized FVB/N embryos and implanted 
into pseudopregnant Swiss-Webster surrogates.  Transgenic founders were identified 
using tail biopsy DNA and PCR primers designed to detect both the L9’S mutation 
(forward: 5’-ctc cgt tct gtc aag ctt g-3’, reverse: 5’-acg agt gct ctg aat tct ctg-3’), and the 
inserted ampicillin cassette within the β3 gene (forward: 5’-gct cat gag aca ata acc ctg-3’, 
reverse: 5’-cag tct tgg aag caa cat cca gc-3’).  Founders were crossed to C57BL/6J 
(Jackson Labs; Bar Harbor, ME) to obtain germline transmission and to establish a 
colony, and transgenic mice were continually backcrossed to C57BL/6J.  Routine 
genotyping was done by multiplex PCR (forward primer #1: 5’-ctc cgt tct gtc aag ctt g-3’, 
forward primer #2: 5’-ctg ctg ctc atc acc gag atc-3’, reverse primer #1: 5’-acg agt gct ctg 
aat tct ctg-3’, reverse primer #2: 5’-cag atg tca ccc aag atg ccg-3’) analysis of tail DNA 
from newly weaned mice.   
 
Mice 
All experiments were conducted in accordance with the guidelines for care and 
use of animals provided by the National Institutes of Health, and protocols were approved 
by the Institutional Animal Care and Use Committee at the California Institute of 
Technology, the University of Colorado at Boulder, or the Rockefeller University.  Mice 
were kept on a standard 12 h light/dark cycle at 22°C and given food and water ad 
libitum.  On postnatal day 21, mice were weaned and housed with same-sex littermates.  
At 21 to 28 days, tail biopsies were taken for genotype analysis by PCR.  Tails were 
digested in 50 mM NaOH at 95ºC for 45 minutes followed by neutralization with 0.5 M 
Tris-Cl, pH 5.5 and subsequent direct analysis by multiplex PCR.  α4L9’A knock-in mice 
used in this study were generated on a mixed C57/129Sv background (1,2), and were 
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backcrossed at least 10 generations to C57BL/6.  Wild type (WT) control mice were 
littermates of α6L9’S transgenic mice. 
 
Locomotor Activity 
Mice used to study locomotion were eight to sixteen weeks old by the beginning 
of an experiment, and were back-crossed to C57BL/6 at least three times.  Back-crossing 
to C57BL/6 did not affect locomotor activity.  Mouse horizontal locomotor activity was 
measured with an infrared photobeam activity cage system (San Diego Instruments; San 
Diego, CA).  Ambulation events were recorded when two contiguous photobeams were 
broken in succession.  Acute locomotor activity in response to nicotinic ligands or other 
agents was studied by recording ambulation events during four 15 sec intervals per 
minute for a designated number of minutes.  For most experiments, groups of eight mice 
were placed in the activity cages (18 X 28 cm) and their baseline level of activity was 
recorded for eight minutes.  Mice were removed from their cage, injected (100 µl per 25 
g body mass), and returned to the cage within 15 sec.  For some experiments, mice were 
pre-injected with saline or an antagonist immediately prior to the start of the experiment, 
followed by challenge with nicotine eight minutes after the start of the experiment.  For 
generation of locomotor activity concentration-response relationship profiles, a group of 
mice was administered saline and, after five to eight days off, each successive dose of 
drug.  For experiments probing sensitization or tolerance, mice were injected once daily 
with saline for three days prior to the start of daily nicotine injections.  For 48 h home 
cage monitoring, mice were isolated in their own cage and habituated to the test room and 
cage for 24 h.  Following this, locomotor activity was recorded in 15 min intervals for 48 
h. 
 
Neurotransmitter Release from Striatal Synaptosomes 
After a mouse was sacrificed by cervical dislocation, its brain was removed and 
placed immediately on an ice-cold platform and brain regions were dissected. Tissues 
from each mouse were homogenized in 0.5 ml of ice-cold 0.32 M sucrose buffered with 5 
mM HEPES, pH 7.5. A crude synaptosomal pellet was prepared by centrifugation at 
12,000 g for 20 min. The pellets were resuspended in “uptake buffer”: 128 mM NaCl, 2.4 
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mM KCl, 3.2 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 25 mM HEPES, pH 7.5, 10 
mM glucose.  For DA uptake, buffer was supplemented with 1 mM ascorbic acid and 
0.01 mM pargyline, whereas for GABA uptake, buffer was supplemented with 1mM 
aminooxyacetic acid.  For [3H]GABA uptake, synaptosomes were incubated for 10 min at 
37°C. [3H]GABA and unlabeled GABA were then added to final concentrations of 0.1 
and 0.25 µM, respectively, and the suspension was incubated for another 10 min.  For 
DA uptake, synaptosomes were incubated at 37° C in uptake buffer for 10 min before 
addition of 100 nM [3H]dopamine (1 µCi for every 0.2 ml of synaptosomes), and the 
suspension was incubated for an additional 5 min.   
All experiments were conducted at room temperature using methods described 
previously (3,4) with modifications for collection into 96-well plates.  In brief, aliquots of 
synaptosomes (80 µl) were distributed onto filters and perfused with buffer (uptake 
buffer containing 0.1% bovine serum albumin and 1 µM atropine with 1 µM nomifensine 
(for DA release) or 0.1 µM NNC-711 [1-(2-(((diphenylmethylene)amino)oxy)ethyl)-
1,2,5,6-tetrahydro-3-pyridinecarboxylic acid hydrochloride]) (for GABA release) at 0.7 
ml/min for 10 min, or buffer for 5 min followed by buffer with 50 nM αCtxMII.  
Aliquots of synaptosomes were then exposed to nicotine or high potassium (20 mM) in 
buffer for 20 sec to stimulate release of [3H]dopamine or [3H]GABA, followed by buffer.  
Fractions (~ 0.1 ml) were collected for 4 min into 96-well plates every 10 sec starting 
from 1 min before stimulation, using a Gilson FC204 fraction collector with a 
multicolumn adapter (Gilson, Inc.; Middleton, WI). Radioactivity was determined by 
scintillation counting using a 1450 MicroBeta Trilux scintillation counter (Perkin Elmer 
Life Sciences) after addition of 0.15 ml Optiphase ‘SuperMix’ scintillation cocktail.  
Instrument efficiency was 40 %. 
Data were analyzed using SigmaPlot 5.0 for DOS. Perfusion data were plotted as 
counts per minute versus fraction number. Fractions collected before and after the peak 
were used to calculate baseline as a single exponential decay. The calculated baseline was 
subtracted from the experimental data.  Fractions that exceeded baseline by 10 % or more 
were summed to give total released cpm and then normalized to baseline to give units of 
release [(cpm-baseline)/baseline] (3). Agonist dose response data were fit to the Hill 
equation (5). 
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Patch-Clamp Electrophysiology  
For slice electrophysiology, transgenic and non-transgenic mice were identified 
by genotyping new litters at ~14 days after birth.  Postnatal day 17-25 (for midbrain), 21-
28 (for locus coeruleus), or 42-56 (for striatum) mice were anesthetized with sodium 
pentobarbital (40 mg/kg, i.p.) followed by cardiac perfusion with oxygenated (95% 
O2/5% CO2) ice-cold glycerol-based artificial CSF (gACSF) containing 252 mM 
glycerol, 1.6 mM KCl, 1.2 mM NaH2PO4, 1.2 mM MgCl2, 2.4 mM CaCl2, 18 mM 
NaHCO3, and 11 mM glucose.  Following perfusion, brains were removed and retained in 
gACSF (0–4°C).  Coronal slices (midbrain, striatum: 250 µm; pons: 200 µm) were cut 
with a microslicer (DTK-1000; Ted Pella, Redding, CA) at a frequency setting of 9 and a 
speed setting of 3.25. Brain slices were allowed to recover for at least 1 h at 32°C in 
regular, oxygenated artificial CSF (ACSF) containing 126 mM NaCl, 1.6 mM KCl, 1.2 
mM NaH2PO4, 1.2 mM MgCl2, 2.4 mM CaCl2, 18 mM NaHCO3, and 11 mM glucose.   
For recordings, a single slice was transferred to a 0.8 ml recording chamber 
(Warner Instruments, RC-27L bath with PH-6D heated platform).  Slices were 
continually superfused with ACSF (1.5–2.0 ml/min) throughout the experiment. Cells 
were visualized with an upright microscope (BX 50WI; Olympus) and near-infrared 
illumination.  Patch electrodes were constructed from Kwik-Fil borosilicate glass 
capillary tubes (1B150F-4; World Precision Instruments, Inc.; Sarasota, FL) using a 
programmable microelectrode puller (P-87; Sutter Instrument Co.; Novato, CA). The 
electrodes had tip resistances of 4.5–8.0 MΩ when filled with internal pipette solution 
(pH adjusted to 7.25 with Tris base, osmolarity adjusted to 290 mOsm with sucrose) 
containing: 135 mM potassium gluconate, 5 mM EGTA, 0.5 mM CaCl2, 2 mM MgCl2, 
10 mM HEPES, 2 mM Mg-ATP, and 0.1 mM GTP.   
Whole-cell recordings were taken at 32°C with an Axopatch 1D amplifier, a 16-
bit Digidata 1322A A/D converter, and pCLAMP9.2 software (all Molecular Devices 
Axon; Sunnyvale, CA).  Data were sampled at 5 kHz and low-pass filtered at 1 kHz. The 
junction potential between the patch pipette and the bath solution was nulled immediately 
prior to gigaseal formation.  Series resistance was uncompensated.  Putative GABAergic 
neurons in the SNr and DAergic neurons in SNc or VTA were identified according to 
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generally accepted criteria (4,6): (1) narrow spikes in GABA neurons vs. broad spikes in 
DA neurons; (2) rapid firing (> 10 Hz) in GABA neurons vs. slow firing (< 5 Hz) in DA 
neurons; (3) SNc DA neurons and to a lesser degree VTA DA neurons, but not SNr 
GABAergic neurons, express hyperpolarization-activated cation current (Ih).  
Noradrenergic neurons in locus coeruleus were identified by the following criteria: (1) 
expression of tyrosine hydroxylase as determined by immunohistochemistry; (2) 
pacemaker firing (< 2 Hz); (3) absence of Ih currents or significant adaptation of 
membrane potential in response to hyperpolarizing current injection; (4) location 
immediately medial to medial parabrachial nucleus.  Striatal cholinergic interneurons 
were identified by the following criteria: 1) cholinergic cells are rare relative to medium 
spiny neurons, large (> 20 µm), and have 1-3 primary dendrites; 2) expression of Ih 
currents and significant membrane potential sag in response to hyperpolarizing current 
injection; 3) some cells do not fire spontaneously whereas other exhibit tonic, irregular 
firing (0-5 Hz).   
To examine the function of somatic nAChRs, nicotine was locally applied using a 
Picospritzer II (General Valve; Fairfield, NJ). Using a piezoelectric translator (Burleigh 
Instruments; Fishers Park, NY), the pipette tip was moved within 20-40 µm of the 
recorded cell over a period of 250 ms starting 300 ms before drug application. Nicotine 
was then puffed at 10–20 psi for 250 ms.  Fifty milliseconds after the application, the 
glass pipette was retracted over a period of 250 ms. 
 
Real Time PCR 
Mouse genomic DNA was obtained from tail biopsies.  Relative quantification of 
total α6 gene copies was performed using the LightCycler 480 system and SYBR Green I 
Master Mix (Roche Diagnostics; Indianapolis, IN).  The α6 (WT and L9’S alleles) locus 
was detected with an α6-specific primer set (forward primer: 5’-gag cgc tgc tga cac ttg-
3’, reverse primer: 5’-ccc ctt gta gca cct agc-3’).  The α4 nicotinic receptor genomic 
locus, which is assumed to be present at one copy per haploid genome, was used as a 
reference target and was detected with α4-specific primers (forward primer: 5’-ctg ctg ctc 
atc acc gag atc-3’, reverse primer: 5’-cag atg tca ccc aag atg ccg-3’).  Crossing point 
values were obtained for target (α6) and reference (α4) genes in serial dilutions of gDNA 
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from non-transgenic and transgenic mice.  The relative ratio of α6 genomic copies in 
non-transgenic versus transgenic mice was calculated according to accepted standards 
(7). 
 
RT-PCR 
For RNA analysis, mice were anesthetized with halothane and sacrificed by 
cervical dislocation.  Brains were rapidly removed and extracted in ice-cold Trizol 
(Invitrogen; Carlsbad, CA) (1 ml Trizol per 100 mg wet brain tissue) aided by dounce 
homogenization.  RNA was purified according to the manufacturer’s instructions, 
resuspended in DEPC-treated H20, and stored at -80ºC.  RNA quality was assessed by 
observing absorbance profiles across a range of wavelengths between 220 nm and 320 
nm.  Spectrophotometric analysis was performed using a ND-1000 spectrophotometer 
(NanoDrop; Wilmington, DE).  Reverse transcription and target amplification was 
performed using SuperScript III One-Step RT-PCR enzyme mix (Invitrogen).  Gene-
specific primers for total α6 mRNA (mutant and WT; forward primer: 5’-gtt tta cac cat 
caa cct cat c-3’, reverse primer: 5’-tta gga gtc tgt gta ctt ggc-3’) or α6L9’S mRNA 
(forward primer: 5’-ctc cgt tct gtc aag ctt g-3’, reverse primer: 5’-acg agt gct ctg aat tct 
ctg-3’) were used to prime first-strand cDNA synthesis and subsequent double-stranded 
PCR product.  In control reactions, Taq DNA polymerase was substituted for SuperScript 
III enzyme mix.  
 
86Rb+ Efflux from Superior Colliculus Synaptosomes 
Nicotine-stimulated 86Rb+ efflux from superior colliculus (SC) was measured as 
described previously(8). SC was dissected from adult mice sedated with halothane and 
sacrificed by cervical dislocation. Tissue was homogenized by hand in 1 ml of ice-cold 
0.32 M sucrose buffered to pH 7.5 with HEPES using a glass/Teflon tissue grinder. After 
homogenization, the grinder was rinsed three times with 0.5 ml of buffered sucrose 
solution. A crude synaptosomal pellet was obtained by centrifugation at 12,000 g for 20 
min. After removal of the sucrose, each pellet was resuspended in load buffer (140 mM 
NaCl, 1.5 mM KCl, 2 mM CaCl2, 1 mM MgSO4, 25 mM HEPES, and 22 mM glucose) 
and placed on ice until incubation with 86RbCl. SC synaptosomes were incubated with 4 
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µCi of 86Rb+ for 30 min in a final volume of 35 µl of load buffer, after which samples 
were collected by gentle filtration onto a 6-mm-diameter Gelman-type A/E glass filter 
and washed once with 0.5 ml of load buffer. Filters containing the synaptosomes loaded 
with 86Rb+ were transferred to a polypropylene platform and superfused for 5 min with 
effluent buffer (135 mM NaCl, 1.5 mM KCl, 5 mM CsCl, 2 mM CaCl2, 1 mM MgSO4, 
25 mM HEPES, 22 mM glucose, 50 nM tetrodotoxin, and 0.1% bovine serum albumin). 
A peristaltic pump applied buffer to the top of the synaptosome containing filter at a rate 
of 2 ml/min, and a second peristaltic pump set at a faster flow rate of 3 ml/min removed 
buffer from the bottom of the platform. The greater speed of the second pump prevented 
pooling of buffer on the filter. Effluent buffer was pumped through a 200 µl Cherenkov 
cell and into a β-Ram detector (IN/US Systems; Tampa, FL). Radioactivity was measured 
for 3 min with a 3 s detection window providing 60 data points for each superfusion. 
Each aliquot was stimulated by 1 of 4 different nicotine concentrations, with a 5 s 
exposure for each concentration. 
 
[125I]-α-conotoxin MII Binding to Brain Sections 
Two mice for each genotype (WT, α6L9’S line 2 and 5) were sedated with 
halothane and sacrificed by cervical dislocation. The brains were removed and rapidly 
frozen by immersion in isopentane (-35°C, 60 s). The frozen brains were wrapped in 
aluminum foil, packed in ice, and stored at -70°C until sectioning. Tissue sections (14 
µm) prepared using an IEC Minotome Cryostat refrigerated to -16°C were thaw mounted 
onto Fisher Superfrost/Plus Microscope Slides.  Mounted sections were stored desiccated 
at -70°C until use. Eight series of sections were collected from each mouse brain. 
Before incubation with [125I]-αCtxMII, three adjacent series of sections from each 
mouse were incubated in binding buffer (144 mM NaCl, 1.5 mM KCl, 2 mM CaCl2, 1 
mM MgSO4, 20 mM HEPES, 0.1% BSA (w/v), pH 7.5) containing 1 mM 
phenylmethylsulfonyl fluoride at 22°C for 15 min.  For all [125I]-αCtxMII binding 
reactions, the standard binding buffer was supplemented with BSA [0.1% (w/v)], 5 mM 
EDTA, 5 mM EGTA, and 10 mg/ml each of aprotinin, leupeptin trifluoroacetate, and 
pepstatin A to protect the ligand from endogenous proteases. The sections were then 
incubated with 0.5 nM [125I]-αCtxMII for 2 h at 22°C.  Samples were washed as follows:  
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once for 30 sec in binding buffer plus 0.1% BSA at 22ºC, twice for 30 sec in binding 
buffer plus 0.1% BSA (4ºC), twice for 5 sec in 0.1X binding buffer plus 0.01% BSA 
(4ºC) and twice for 5 sec in 5 mM HEPES, pH 7.5 (0ºC).  Sections were initially dried 
with a stream of air, then by overnight storage (22°C) under vacuum. Mounted, 
desiccated sections were apposed to film (1–3 days, Kodak MR film).  
 
[125I]-Epibatidine Binding to Membranes 
Each mouse was sacrificed by cervical dislocation.  The brain was removed and 
placed on an ice-cold platform. Tissue was collected from superior colliculus, thalamus, 
striatum (CPu and dorsal NAc), and olfactory tubercle, then homogenized in ice-cold 
hypotonic buffer (144 mM NaCl; 0.2 mM KCl; 0.2 mM CaCl2; 0.1 mM MgSO4; 2 mM  
HEPES; pH 7.5) using a glass-Teflon tissue grinder(9). Particulate fractions were 
obtained by centrifugation at 20,000 g (15 min, 4ºC; Sorval RC-2B centrifuge). The 
pellets were resuspended in fresh homogenization buffer, incubated at 22ºC for 10 min, 
then harvested by centrifugation as before.  Each pellet was washed twice more by 
resuspension/centrifugation, then stored (in pellet form under homo-genization buffer) at 
-70ºC until use. Protein was quantified with a Lowry assay using bovine serum albumin 
as the standard. 
Binding of [125I]-epibatidine was quantified using a modified version of the 
methods previously described for [3H]-epibatidine (9). Incubations were per-formed in 
96-well polystyrene plates, in 30 ml of binding buffer (144 mM NaCl; 1.5 mM KCl; 2 
mM CaCl2; 1 mM MgSO4; 20 mM HEPES; pH 7.5). Plates were covered to minimize 
evaporation during incubation, and all incubations progressed for 2 h at 22ºC. Saturation 
binding experiments were performed for membrane preparations from each brain region, 
using a [125I]-epibatidine ligand concentration of 200 pM. Binding reactions were 
terminated by filtration of samples onto a single thickness of polyethyleneimine-soaked 
(0.5% w/v in binding buffer) GFA/E glass fiber filters (Gelman Sciences; Ann Arbor, 
MI) using an Inotech Cell Harvester (Inotech; Rockville, MD, U.S.A.). Samples were 
subsequently washed six times with ice-cold binding buffer. Bound ligand was quantified 
by gamma counting at 83-85% efficiency, using a Packard Cobra counter.  In experiments 
with competitive, unlabeled αCtxMII, the amount of membrane protein added was 
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chosen to produce maximum binding of ligand to the tissue of approximately 40 Bq/well 
(less than 10% of total ligand added, minimizing the effects of ligand depletion). For 
αCtxMII (50 nM), the medium was supplemented with bovine serum albumin (0.1% 
w/v) as a carrier protein.  For all experiments, non-specific binding was determined in the 
presence of 1 mM (-)-nicotine tartrate. 
 
Immunohistochemistry and Spectral Confocal Imaging 
Coronal brain slices cut for patch-clamp recording were removed from the 
recording chamber and immediately fixed (4% PFA in PBS, pH 7.4) for 45 min at 4ºC.  
Slices were permeabilized (20 mM Hepes, pH 7.4, 0.5% Triton X-100, 50 mM NaCl, 3 
mM MgCl2, 300 mM sucrose) for 1 h at 4ºC followed by blocking (0.1% Triton X-100, 
5% donkey serum in TBS) for 1 h at room temperature.  Slices were incubated overnight 
at 4ºC in rabbit anti-tyrosine hydroxylase (TH) primary antibody (Pel-Freez; Rogers, AR) 
(diluted 1:100 in 0.1% Triton X-100, 5% donkey serum in TBS), washed three times in 
TBST (0.1% Triton X-100 in TBS), incubated for 1 h at room temperature in goat anti-
rabbit Alexa 488 secondary antibody (Molecular Probes; Eugene, OR) (diluted 1:500 in 
0.1% Triton X-100, 5% donkey serum in TBS), and washed three times in TBST.   
Slices were mounted and imaged with a Nikon (Nikon Instruments, Melville, NY) 
C1 laser-scanning confocal microscope system equipped with spectral imaging 
capabilities and a Prior (Rockland, ME) remote-focus device.  A Nikon Plan Apo 10X 
objective was used, and pinhole diameter was 30 µm.  Sections were imaged at 12-bit 
intensity resolution over 512 X 512 pixels at a pixel dwell time of 6 µs.  Alexa 488 was 
excited with an argon laser at 488 nm.  Imaging was carried out using the Nikon C1si 
DEES grating and spectral detector with 32 parallel photomultiplier tubes.  Signal from 
Alexa 488 was unmixed from background autofluorescence similar to our previous 
studies (4,10,11). 
 
Statistics and Data Analysis 
Physiology, neurochemistry, and real time PCR data are reported as mean + SEM.  
Statistical significance (p < 0.05) was determined with a t test for continuous data 
meeting parametric assumptions for normality and equal variance.  DA release 
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parameters and behavior data were analyzed for significance with two-way or one-way 
ANOVA, respectively, with Tukey post hoc analysis. 
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Figure S1 - Construction of α6 Leu9’Ser BAC transgenic mice.   
(A) BAC recombineering to generate α6L9’S targeting vector.  Mouse BAC clone RP24-
149I12 contains 156 kb of mouse genomic DNA, including the α6 (Chrna6) and β3 
(Chrnb3) nicotinic receptor genes.  A two-step homologous recombination procedure was 
carried out in E. coli to generate the α6L9’S allele.  First, a region of α6 exon 5 containing 
the Leu9’ residue was replaced with an rpsL-neo selection cassette.  Second, non-
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selectable DNA containing the mutant Leu9’Ser sequence was inserted into exon 5 via 
counter-selection.  The resulting BAC had no ectopic DNA sequences and differed from 
the WT α6 gene only at the Leu9’ residue.  The β3 nAChR gene on this BAC was 
inactivated by disruption of the start codon with an ampicillin cassette.   
(B) Genomic DNA sequence of WT and transgenic mice demonstrate the presence of WT 
and Leu9’Ser α6 alleles in transgenic mice, and only WT α6 alleles in non-transgenic 
mice.   
(C) Analysis of genomic DNA samples to identify non-transgenic and transgenic mice.  
Primers designed to amplify control (α4 nAChR) and α6L9’S genomic DNA were used in 
multiplex PCR reactions to genotype weanling mice.   
(D) Transgene copy number analysis.  Real time quantitative PCR analysis on genomic 
DNA was used to quantify the number of α6L9’S BAC transgenes in two independently 
derived transgenic lines (line 2 and line 5).   
(E) Characterization of α6 (WT and L9’S) mRNA expression in line 2 and 5 with RT-
PCR.  Whole-brain RNA samples from non-transgenic and transgenic mice were reverse-
transcribed and amplified with primers specific for total or L9’S α6 cDNA.   
(F) Correct regional expression of α6* receptors in α6L9’S mice.  Brains from WT and 
α6L9’S mice were sectioned and labeled with [125I]-αCtxMII.  Representative sections 
through striatum (bregma +1.4 mm), optic tract / hippocampus (bregma -2.8 mm), and 
superior colliculus (bregma -3.9 mm) are shown.   
(G) Quantitative analysis of α6* receptor expression.  Brain regions known to express 
α6* receptors were dissected and labeled with [125I]-epibatidine in the presence or 
absence of competing, unlabeled αCtxMII.  Raw binding values for αCtxMII-resistant 
receptors are shown in the upper panel.  αCtxMII-sensitive receptors (predominantly 
α6*) are expressed as the percent of total epibatidine binding.  ST, striatum; OT, 
olfactory tubercle; SC, superior colliculus; TH, thalamus. 
Data are reported as mean + SEM.  *, p < 0.05; **, p < 0.01.
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Figure S2 – Dopamine release parameters for nicotine.  WT, α6L9’S line 2 and α6L9’S line 
5 striata were dissected and prepared for [3H]DA release as described in Experimental 
Procedures.  Striatum (ST) and olfactory tubercle (OT) were handled separately.  
Concentration-response data were fitted to the Hill equation.  EC50 and Rmax values are 
shown for each condition.  Parallel samples were stimulated with KCl (20 mM) as a 
positive control.  EC50 values are in µM.  20 mM K+ and Rmax values are in DA release 
units.   
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Figure S3 – GABA release parameters for nicotine.  WT, α6L9’S line 2 and α6L9’S line 5 
striata were dissected and prepared for [3H]DA release as described in Experimental 
Procedures.  Striatum (ST) and olfactory tubercle (OT) were combined.  Concentration-
response data were fitted to the Hill equation.  EC50 and Rmax values are shown for each 
condition.  MII-sensitive activity could not be fit and EC50 and Rmax values could not be 
derived.  Parallel samples were stimulated with KCl (20 mM) as a positive control.  EC50 
values are in µM.  20 mM K+ and Rmax values are in DA release units. 
 17 
 
 
Figure S4 - Hypersensitive α6* receptors in superior colliculus of α6L9’S mice.  Superior 
colliculi from WT and α6L9’S (line 2 and 5) were dissected and a crude synaptosomal 
pellet was prepared.  Following 86Rb+ loading, samples were stimulated with a range of 
nicotine concentrations and 86Rb+ efflux was measured.  Data were fitted to the Hill 
equation, and a concentration response curve for each mouse line (n = 6) is shown for 
total 86Rb+ efflux (left panel).  To determine the relative contribution of α6* and non-α6* 
receptors to the total efflux profile, parallel samples were incubated with αCtxMII (50 
nM).  αCtxMII-sensitive (center panel) and resistant (right panel) components are shown 
for each mouse line.   
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Figure S5 – Dopamine release parameters for TC 2429 and TC 2403.  WT, α6L9’S line 2 
and α6L9’S line 5 striata were dissected and prepared for [3H]DA release as described in 
Experimental Procedures.  Striatum (ST) and olfactory tubercle (OT) were combined.  
Concentration-response data were fitted to the Hill equation.  EC50 and Rmax values are 
shown for each condition.  Parallel samples were stimulated with nicotine (10 µM) as a 
positive control and to demonstrate partial or full agonism.  EC50 values are in µM.  10 
µM nicotine and Rmax values are in DA release units.   
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Figure S6 - Nicotinic current density in WT and α6L9’S VTA neurons.  VTA neurons 
from WT or α6L9’S (line 2 and 5) were locally stimulated with nicotine (1 µM).  Current 
responses (pA) were normalized to cell capacitance (pF) values for each cell. 
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Figure S7 – Additional analysis of increased channel noise in VTA of α6L9’S mice.   
Average RMS noise values for voltage clamp recordings from α6L9’S VTA DA neurons 
under control conditions and in the presence of the indicated drug is shown.  Because 
results were similar in line 2 and line 5, data from both lines were pooled.  
Data are reported as mean + SEM.  n.s., not significant; *, p < 0.05.
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Figure S8 – Electrophysiological analysis of substantia nigra pars compacta (SNc) 
neurons.   
(A) Concentration-response relationship for hypersensitive nicotinic responses in SNc 
neurons from WT and α6L9’S mouse lines.  The average peak amplitude of the cellular 
response for each mouse line and each nicotine concentration is plotted.   
(B) Quantification of firing responses in WT and α6L9’S SNc DA neurons.  Peak 
instantaneous firing frequency values for each nicotine (1 µM) application (one per cell) 
were derived and averaged for each mouse line.  Average peak values are compared with 
the average baseline firing rate for the same group of cells.  
(C) Quantification of channel noise increase in α6L9’S mice.  RMS noise values for 
voltage clamp recordings from SNc DA neurons in the presence and absence of αCtxMII 
is shown.   
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Data are reported as mean + SEM.  n.s., not significant; **, p < 0.01; ***, p < 0.001.  . 
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Figure S9 – Equivalent dopamine tone in WT and α6L9’S VTA.  VTA dopamine neurons 
from WT (top panel) or α6L9’S (bottom panel) mice were recorded in whole-cell 
configuration.  Baseline firing (control) and firing during bath application of sulpiride (10 
µM) was recorded (i).  Nicotine (1 µM) was puff applied (arrow; (ii)) both under baseline 
firing conditions and after 5 min of sulpiride application.  Results were similar in line 2 
(n = 2) and line 5 (n = 3).  Representative traces are shown.  Scale bars: 70 mV, 2.5 s.
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Figure S10 – Analysis of striatal cholinergic interneurons from WT and α6L9’S mice.   
(A) Identification of striatal cholinergic interneurons.  Large, aspiny neurons from dorsal 
striatum often fired spontaneously (i; scale bars: 80 mV, 4 s) but in an irregular fashion, 
with periods of regular firing, bursts, and pauses in firing accompanied with a 
hyperpolarization in the resting membrane potential.  Cholinergic cells expressed 
prominent Ih (ii; 400 pA, 0.4 s; Vm stepped from -60 mV to -70, -80, -90, -100, -110, and 
-120) and exhibited a substantial sag in the membrane potential in response to 
hyperpolarizing current pulses (iii; scale bars: 80 mV, 0.4 s; current (pA) pulses: +20, 0, -
20, -40, -60, -80, -100). 
(B) Spontaneous firing properties of WT and α6L9’S cholinergic interneurons.  Cells from 
the indicated group (WT, n = 21; line 2, n = 22; or line 5, n = 23) were classified as not 
firing (0 Hz), irregular firing, or regular firing (1-5 Hz).   
(C) Resting membrane potential in WT and α6L9’S cholinergic interneurons is plotted.  
n.s., not significant; *, p < 0.05. 
(D) Ih in cholinergic interneurons is largely unchanged in α6L9’S mice.  Striatal 
cholinergic interneurons from WT, line 2, and line 5 were recorded in whole-cell 
configuration at a holding potential of -60 mV.  Membrane voltage was stepped to the 
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indicated hyperpolarized potential, and hyperpolarization-activated currents were 
measured.  These currents were defined as the difference between the steady-state current 
and the initial current level after the capacitive transient (inset).      
(E) Hyperpolarizing current-induced voltage sag is unchanged in α6L9’S mice.  Striatal 
cholinergic interneurons from WT, line 2, and line 5 were recorded in whole-cell 
configuration in current clamp mode.  Membrane potential, including the sag in the 
membrane potential that is dependent on Ih, was measured in response to the indicated 
hyperpolarizing current injections.  Voltage sag for each current injection was defined as 
the difference between the peak hyperpolarized potential and the steady state potential at 
the end of the current pulse (inset).    
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Figure S11 - Summary of nicotine EC50 values for functional nAChRs in α6L9’S mice 
demonstrates DA neuron hypersensitivity.  For neurochemistry experiments (left panel; 
[3H]DA release, [3H]GABA release, and 86Rb+ efflux), nicotine EC50 values are plotted 
for α6L9’S line 2 and 5.  For slice electrophysiology (right panel), approximate EC50 
values for picospritzer-activated currents are plotted for α6L9’S VTA DA and LC NE 
neurons.  OT, olfactory tubercle; ST, striatum; SC, superior colliculus.
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